Clinical trial
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
NCT00234442 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00234442 |
|---|---|
| Title | Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer |
| Official title | A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain Neoplasms, Non Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Iressa (Gefitinib) |
| Enrollment | 47 |
| Start date | Jul 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Oct 7, 2005 |
| Last update posted | Jun 30, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: